Disclosure pursuant to Paragraph 9.1 (a) of the Chapter VIII of SEBI Master Circular No. SEBI/HO/DDHS/PoD1/P/CIR/2024/54 dated May 22, 2024.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has filed a routine SEBI-mandated disclosure listing its privately placed debt securities for the half-year ended March 31, 2025. The company has 6 outstanding debt instruments totaling Rs 10,000 crore in face value, with Rs 7,000 crore currently outstanding. This includes three long-term bonds of Rs 5,000 crore (maturing in 2026 and 2027 at around 7.97-7.99% coupon) and three commercial papers of Rs 2,000 crore outstanding. A Rs 3,000 crore commercial paper that matured in January 2025 has been fully repaid, reducing the outstanding balance. All instruments carry semi-annual or shorter payment frequencies with no embedded options.
This is a standard regulatory disclosure with no new borrowing or material change. Shareholders can note that Mankind Pharma has Rs 7,000 crore of privately placed debt outstanding, with manageable near-term maturities (Rs 2,000 crore of commercial papers due in April and October 2025). No impact on stock price is expected from this routine filing.